Review Article

Elevated Lp(a): Guidance for Identifying and Managing Patients

Authors: Daniel E. Hilleman, PharmD, James L. Vacek, MD, MS, James M. Backes, PharmD

Abstract

Lipoprotein(a) (Lp(a)) is a unique low-density lipoprotein-like lipoprotein that is considered an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis. The Lp(a) molecule also contains apolipoprotein A and apolipoprotein B, which collectively promote atherosclerosis, thrombosis, and inflammation. Lp(a) is highly genetic and minimally responsive to nonpharmacological measures. Lp(a) serum levels ≥125 nmol/L are associated with increased ASCVD risk, but this threshold has not been accepted universally. Elevated Lp(a) is the most common genetic dyslipidemia affecting approximately 20% of the general population. Certain currently available lipid-lowering drugs, including the proprotein convertase subtilisin/kexin type 9 therapies, produce moderate reductions in Lp(a); however, none are indicated for the treatment of elevated Lp(a). There are currently four investigational RNA-based therapeutic agents that reduce Lp(a) by 70% to 100%. Two of these agents are being evaluated for ASCVD risk reduction in adequately powered outcomes trials, with results expected in 2 to 3 years. Until such therapies become available and demonstrate favorable clinical outcomes, strategies for elevated Lp(a) primarily involve early and intensive ASCVD risk factor management.
Posted in: Cardiovascular Disease40

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2019;13:374–392.
 
2. Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease. A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2022;42:e48–e60.
 
3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1082–e1143.
 
4. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2019;41:111–188.
 
5. Zafrir B, Aker A, Saliba W. Lipoprotein(a) testing in clinical practice: real-life data from a large healthcare provider. Eur J Prev Cardiol 2022;29:e331–e333.
 
6. Sheridan C. RNA drugs lower lipoprotein(a) and genetically driven cholesterol. Nat Biotechnol 2022;40:983–985.
 
7. Berg K, Dahlén G, Frick MH. Lp(a) lipoprotein and pre-β1-lipoprotein in patients with coronary heart disease. Clin Genet 1974;6:230–235.
 
8. Brunner C, Lobentanz E-M, Pethö-Schramm A, et al. The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells*. J Biol Chem 1996;271:32403–32410.
 
9. Kinpara K, Okada H, Yoneyama A, et al. Lipoprotein(a)-cholesterol: a significant component of serum cholesterol. Clin Chim Acta 2011;412: 1783–1787.
 
10. Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res 2016;57:745–757.
 
11. Tsimikas S, Marcovina SM. Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week. J Am Coll Cardiol 2022;80: 934–946.
 
12. Virani SS, Koschinsky ML, Maher L, et al. Global think tank on the clinical considerations and management of lipoprotein(a): the top questions and answers regarding what clinicians need to know. Prog Cardiovasc Dis 2022;73:32–40.
 
13. Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat Rev Cardiol 2019;16:305–318.
 
14. Zheng KH, Tsimikas S, Pawade T, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol 2019;73:2150–2162.
 
15. Coassin S, Erhart G, Weissensteiner H, et al. A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction. Eur Heart J 2017;38:1823–1831.
 
16. Schachtl-Riess JF, Kheirkhah A, Grüneis R, et al. Frequent LPA KIV-2 variants lower lipoprotein(a) concentrations and protect against coronary artery disease. J Am Coll Cardiol 2021;78:437–449.
 
17. Gudbjartsson DF, Thorgeirsson G, Sulem P, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol 2019;74: 2982–2994.
 
18. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022;43:3925–3946.
 
19. Newman CB, Blaha MJ, Boord JB, et al. Lipid management in patients with endocrine disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2020;105:3613–3682.
 
20. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol 2021;37:1129–1150.
 
21. Sosnowska B, Surma S, Banach M. Targeted treatment against lipoprotein (a): the coming breakthrough in lipid lowering therapy. Pharmaceuticals 2022; 15:1573.
 
22. Yeang C, Witztum JL, Tsimikas S. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res 2021;62:100053.
 
23. Kaiser Y, Singh SS, Zheng KH, et al. Lipoprotein(a) is robustly associated with aortic valve calcium. Heart 2021;107:1422–1428.
 
24. Bhatia HS, Ma GS, Taleb A, et al. Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis. Atherosclerosis 2022;349:144–150.
 
25. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361:2518–2528.
 
26. Kamstrup PR, Tybjærg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301: 2331–2339.
 
27. Erqou S, Kaptoge S, Perry P, et al. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;22: 412–423.
 
28. Deloukas P, Kanoni S, Willenborg C, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013;45: 25–33.
 
29. Burgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol 2018;3:619–627.
 
30. Madsen CM, Kamstrup PR, Langsted A, et al. Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study. Arterioscler Thromb Vasc Biol 2020;40:255–266.
 
31. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013;368:503–512.
 
32. Capoulade R, Chan KL, Yeang C, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol 2015;66: 1236–1246.
 
33. Bittner VA, Szarek M, Aylward PE, et al. Effect of alirocumab on lipoprotein (a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol 2020;75:133–144.
 
34. Szarek M, Bittner VA, Aylward P, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J 2020;41:4245–4255.
 
35. Kim KA, Park H-J. New therapeutic approaches to the treatment of dyslipidemia 2: LDL-C and Lp(a). J Lipid Atheroscler 2023;12:37–46.
 
36. Tsimikas S, Stroes ESG. The dedicated “Lp(a) clinic”: a concept whose time has arrived? Atherosclerosis 2020;300:1–9.
 
37. Novartis Pharmaceuticals. Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients with CVD (Lp(a)HORIZON). https://clinicaltrials.gov/study/NCT04023552. Published 2023. Accessed April 24, 2023. 
 
38. Koren MJ, Moriarty PM, Baum SJ, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med 2022;28:96–103.
 
39. Sohn W, Winkle P, Neutel J, et al. Pharmacokinetics, pharmacodynamics, and tolerability of olpasiran in healthy Japanese and non-Japanese participants: results from a Phase I, single-dose, open-label study. Clin Ther 2022;44: 1237–1247.
 
40. O’Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med 2022;387: 1855–1864.
 
41. Amgen. Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial. https://clinicaltrials.gov/study/NCT05581303. Published 2023. Accessed April 25, 2023.
 
42. Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA 2022;327:1679–1687.
 
43. Pokrovsky SN, Afanasieva OI, Safarova MS, et al. Specific Lp(a) apheresis: a tool to prove lipoprotein(a) atherogenicity. Atheroscler Suppl 2017;30: 166–173.
 
44. O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 2019;139:1483–1492.
 
45. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140:e596–e646.
 
46. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227–3337.
 
47. Malik MB, Goyal A. Cardiac Exam. Treasure Island, FL: StatPearls; 2023.
 
48. Safarova MS, Moriarty PM. Lipoprotein apheresis: current recommendations for treating familial hypercholesterolemia and elevated lipoprotein(a). Curr Atheroscler Rep 2023;25:391–404.
 
49. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2022;80:1366–1418.
 
50. Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res 2016;57:526–537.